ArticlePloS one2010
A simple and sensitive method for measuring tumor-specific T cell cytotoxicity.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02662348 (T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System), which is not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
Who cites it
43 citing papers in PubMed, 88 citations in OpenAlex.
- Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6/E7 mRNA vaccine in an HPV-positive tumor.Molecular therapy. Oncology · 2026Article
- Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival.Journal for immunotherapy of cancer · 2025Article
- Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer.Molecular therapy. Methods & clinical development · 2025Article
- Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia.Cancer cell · 2025Article
- Article
- Imaging-Based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids.Advanced healthcare materials · 2024Review
- A dual-luciferase bioluminescence system for the assessment of cellular therapies.Molecular therapy. Oncology · 2024Article
- A Promising New Model: Establishment of Patient-Derived Organoid Models Covering HPV-Related Cervical Pre-Cancerous Lesions and Their Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.Blood advances · 2023Article
- Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.Journal of hematology & oncology · 2023Article
- Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells.Cancers · 2022Article
- Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein.Bioengineered · 2022Article
- Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity.Scientific reports · 2022Article
- Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model.Molecular therapy oncolytics · 2022Article
- Single-cell RNA sequencing reveals a strong connection betweenMolecular therapy oncolytics · 2021Article
- NK cell receptor and ligand composition influences the clearance of SARS-CoV-2.The Journal of clinical investigation · 2021Article
- A novel thermostable beetle luciferase based cytotoxicity assay.Scientific reports · 2021Article
- Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.Nature protocols · 2021Review
- An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.Theranostics · 2021Article
- Promoter choice: Who should drive the CAR in T cells?PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
A simple and sensitive method to quantitatively measure the cytolytic effect of tumor-specific T killer cells is highly desirable for basic and clinical studies. Chromium (51Cr) release assay has been the "gold standard" for quantifying cytolytic activities of cytotoxic T lymphocytes (CTLs) against target cells and this method is still being used in many laboratories. However, a major drawback of this method is the use of radioactive materials, which is inconvenient to handle because of environmental safety concerns and expensive due to the short half-life of the isotope. Consequently, several nonradioactive methods have been reported recently. Here we report a new method that we recently developed for quantifying antigen-specific cytolytic activity of CTLs. This method fully exploits the high sensitivity and the relative simplicity of luciferase quantitative assay. We initially expected the released luciferase in the supernatant to be the adequate source for monitoring cell death. However, to our total surprise, incubation of these killer T cells with the tumor cell targets did not result in significant release of luciferase in the culture medium. Instead, we found that the remaining luciferase inside the cells could accurately reflect the overall cell viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.